Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (vol, pg, 2019)

被引：4
|
作者：
Xu, Jiangsheng
Liu, Yunhua
Li, Yujing
Wang, Hai
Stewart, Samantha
Van der Jeught, Kevin
Agarwal, Pranay
Zhang, Yuntian
Liu, Sheng
Zhao, Gang
Wan, Jun
Lu, Xiongbin
He, Xiaoming
机构：
[1] University of Maryland,Fischell Department of Bioengineering
[2] The Ohio State University,Comprehensive Cancer Centre
[3] The Ohio State University,Department of Biomedical Engineering
[4] Indiana University School of Medicine,Department of Medical and Molecular Genetics
[5] Indiana University School of Medicine,Melvin and Bren Simon Cancer Centre
[6] University of Science and Technology of China,Department of Electronics Science and Technology
[7] University of Maryland,Robert E. Fischell Institute for Biomedical Devices
[8] University of Maryland,Marlene and Stewart Greenebaum Comprehensive Cancer Centre
来源：
NATURE NANOTECHNOLOGY | 2020年 / 15卷 / 04期
关键词：
D O I：
10.1038/s41565-020-0635-3
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [21] Combination therapeutic strategy to fight against triple-negative breast cancer
    Svajda, Laura
    Randelovic, Ivan
    Surguta, Sara Eszter
    Baranyi, Marcell
    Kenessey, Istvan
    Cserepes, Mihaly
    Tovari, Jozsef
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum (vol 9, pg 1401, 2019)
    Zhao, Zitong
    Li, Lin
    Du, Peina
    Ma, Liying
    Zhang, Weimin
    Zheng, Leilei
    Lan, Bo
    Zhang, Bailin
    Ma, Fei
    Xu, Bo
    Zhan, Qimin
    Song, Yongmei
    THERANOSTICS, 2023, 13 (04): : 1287 - 1288
  • [23] Therapeutic targeting of aberrant sialylation for prevention of chemoresistance and metastasis in triple negative breast cancer
    Pindiprolu, Sai Kiran S. S.
    Madhan, Jitender
    Srinivasarao, Dadi A.
    Dasari, Nagasen
    Kumar, Chirravuri. S. Phani
    Katta, Chantibabu
    Jyothi, Vaskuri G. S. Sainaga
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2023, 86
  • [24] Targeting the glycolytic pathway as an effective therapeutic approach for triple-negative breast cancer
    Pelicano, Helene
    Zhang, Wan
    Hammoudi, Naima
    Pusztai, Lajos
    Dai, Jiale
    Huang, Peng
    CANCER RESEARCH, 2010, 70
  • [25] Inhibiting ribosomal proteins with a small molecule: Therapeutic strategy for triple negative breast cancer
    Dheeraj, Arpit
    Tailor, Dhanir
    Resendez, Angel
    Marques, Fernando Jose
    Bermudez, Abel
    Pitteri, Sharon
    Malhotra, Sanjay
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Innovative therapeutic strategy against triple-negative breast cancer based on the p300-targeting curcumin analogues
    Masuda, Tatsuya
    Watanabe, Takayoshi
    Rohmad, Yudi U.
    Ozaki, Toshinori
    Nakamura, Rikiya
    Edy, Meiyanto
    Kamikubo, Yasuhiko
    CANCER SCIENCE, 2025, 116 : 188 - 188
  • [27] ADAM-17: a novel therapeutic target for triple negative breast cancer (vol 24, pg 362, 2013)
    McGowan, P. M.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2199 - 2199
  • [28] Wortmannin as targeted therapeutic agent for the treatment of triple-negative breast cancer (vol 15, pg 95, 2016)
    Li, Jian
    Liu, Fei
    Liu, Yang
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2017, 16 (01) : CP18 - CP18
  • [29] Effect of therapeutic targeting of the oncogene EMP2 in triple-negative breast cancer on tumor load
    Wadehra, Madhuri
    Kiyohara, Meagan
    Fu, Maoyong
    Gordon, Lynn K.
    Braun, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
    Lee, Kha-Liang
    Kuo, Yung-Che
    Ho, Yuan-Soon
    Huang, Yen-Hua
    CANCERS, 2019, 11 (09)
12345